New hope for tough prostate cancer: early trial of ACE-232 begins

NCT ID NCT06801236

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 13 times

Summary

This early-phase study tests a new drug called ACE-232 in about 67 men with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The main goals are to check the drug's safety, find the best dose, and see early signs it might help control the cancer. Participants must have already tried other standard treatments without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Carolina Urologic Research Center

    RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • Fred Hutchinson Cancer Research Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Harvard Medical School-Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • M Health Fairview Clinics and Surgery Center

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Moffitt Cancer Center, Tampa

    RECRUITING

    Tampa, Florida, 33612, United States

  • University of California San Diego, Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Xcancer (Urology Cancer Center)

    RECRUITING

    Omaha, Nebraska, 68130, United States

Conditions

Explore the condition pages connected to this study.